SHLG(SH:600848) Xin Lang Cai Jing·2025-12-24 09:35Core Viewpoint - The event "Empower Together, Create the Future" focused on the biopharmaceutical industry, aiming to build a high-end ecological platform for precise connections between industry and capital institutions, supporting Shanghai's goal of becoming a global innovation hub in biomedicine [4]. Group 1: Company Strategy and Development - Lingang Group has been operating in park development for over 40 years, with 28 parks across 16 districts and over 24,000 enterprises gathered [5]. - The group positions itself as a "first-class park innovation ecological integrator and general operator," accelerating the cultivation of cutting-edge industries like biomedicine [5]. - The biopharmaceutical sector is one of Shanghai's three strategic leading industries, with Lingang Group focusing on creating a "Life Blue Bay" in the Lingang New Area, emphasizing research and high-end manufacturing [5][6]. Group 2: Investment and Funding - Lingang Group aims to leverage a fund size of 170 billion yuan through a "fund + base" model to construct a relay funding acceleration system for the biopharmaceutical industry [5]. - The Lingchuang Blue Bay Fund has signed investment agreements with several innovative companies, emphasizing a dual linkage between capital investment and industrial base support [9]. Group 3: Industry Trends and Innovations - The event highlighted key growth areas in biomedicine, including cell and gene therapy, antibody drugs, and innovative vaccines, aiming to establish a trillion-yuan biopharmaceutical industry in Shanghai [7]. - The "nucleic acid drug clinical transformation concept verification center" was inaugurated to support the entire chain of nucleic acid drug development, enhancing the ecosystem for innovation in this field [10]. Group 4: Collaborative Efforts and Ecosystem Building - The event featured discussions on how the "fund + base + ecosystem" model can enhance production capabilities and drive high-quality development in the biopharmaceutical sector [11]. - Collaborations were established with companies like Medtronic to integrate resources and deepen cooperation in the medical device industry, contributing to the development of a high-quality innovation service system in Shanghai [8].